Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

NCT07633613 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Carcinoma (NSCLC)
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Blood sampling
PROCEDURE: Tumor biopsies for biobank establishment (optional)

Sponsor

Centre Antoine Lacassagne